These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7731677)

  • 1. N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation.
    Leng P; Brown DR; Shivakumar CV; Deb S; Deb SP
    Oncogene; 1995 Apr; 10(7):1275-82. PubMed ID: 7731677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein.
    Brown DR; Deb S; Muñoz RM; Subler MA; Deb SP
    Mol Cell Biol; 1993 Nov; 13(11):6849-57. PubMed ID: 8413278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
    Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
    Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A genetic approach to mapping the p53 binding site in the MDM2 protein.
    Freedman DA; Epstein CB; Roth JC; Levine AJ
    Mol Med; 1997 Apr; 3(4):248-59. PubMed ID: 9131587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The human oncoprotein MDM2 uses distinct strategies to inhibit transcriptional activation mediated by the wild-type p53 and its tumor-derived mutants.
    Brown DR; Deb D; Frum R; Hickes L; Munoz R; Deb S; Deb SP
    Int J Oncol; 2001 Mar; 18(3):449-59. PubMed ID: 11179471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repression of p53-mediated transcription by MDM2: a dual mechanism.
    Thut CJ; Goodrich JA; Tjian R
    Genes Dev; 1997 Aug; 11(15):1974-86. PubMed ID: 9271120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.
    Liu WL; Midgley C; Stephen C; Saville M; Lane DP
    J Mol Biol; 2001 Nov; 313(4):711-31. PubMed ID: 11697899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MdmX protects p53 from Mdm2-mediated degradation.
    Jackson MW; Berberich SJ
    Mol Cell Biol; 2000 Feb; 20(3):1001-7. PubMed ID: 10629057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Over-expression of the human MDM2 p53 binding domain by fusion to a p53 transactivation peptide.
    Liu Z; Olejniczak ET; Fesik SW
    Protein Expr Purif; 2004 Oct; 37(2):493-8. PubMed ID: 15358376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MdmX inhibits Smad transactivation.
    Kadakia M; Brown TL; McGorry MM; Berberich SJ
    Oncogene; 2002 Dec; 21(57):8776-85. PubMed ID: 12483531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physical and functional interactions between PML and MDM2.
    Wei X; Yu ZK; Ramalingam A; Grossman SR; Yu JH; Bloch DB; Maki CG
    J Biol Chem; 2003 Aug; 278(31):29288-97. PubMed ID: 12759344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2.
    Dumaz N; Meek DW
    EMBO J; 1999 Dec; 18(24):7002-10. PubMed ID: 10601022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a domain within MDMX-S that is responsible for its high affinity interaction with p53 and high-level expression in mammalian cells.
    Rallapalli R; Strachan G; Tuan RS; Hall DJ
    J Cell Biochem; 2003 Jun; 89(3):563-75. PubMed ID: 12761890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mdm2: keeping p53 under control.
    Piette J; Neel H; Maréchal V
    Oncogene; 1997 Aug; 15(9):1001-10. PubMed ID: 9285554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6.
    Marston NJ; Jenkins JR; Vousden KH
    Oncogene; 1995 May; 10(9):1709-15. PubMed ID: 7753547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function.
    Marston NJ; Crook T; Vousden KH
    Oncogene; 1994 Sep; 9(9):2707-16. PubMed ID: 8058335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mdm2 inhibits the apoptotic function of p53 mainly by targeting it for degradation.
    Yap DB; Hsieh JK; Lu X
    J Biol Chem; 2000 Nov; 275(47):37296-302. PubMed ID: 10980197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene.
    Chen J; Lin J; Levine AJ
    Mol Med; 1995 Jan; 1(2):142-52. PubMed ID: 8529093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-terminal region of USP7/HAUSP is critical for deubiquitination activity and contains a second mdm2/p53 binding site.
    Ma J; Martin JD; Xue Y; Lor LA; Kennedy-Wilson KM; Sinnamon RH; Ho TF; Zhang G; Schwartz B; Tummino PJ; Lai Z
    Arch Biochem Biophys; 2010 Nov; 503(2):207-12. PubMed ID: 20816748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity.
    Candau R; Scolnick DM; Darpino P; Ying CY; Halazonetis TD; Berger SL
    Oncogene; 1997 Aug; 15(7):807-16. PubMed ID: 9266967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.